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executive of a London district health authority, that it 
return for assured funding of research and develop. 
ment by the NHS, the selection of research priorities 
would have to take into account the needs of the NHS, 
and that the quality of such research would need to be 
better than could be purchased from elsewhere. This 
produced a brisk flurry of 'Letters to the Editor' [3]. 
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Secretary of State and the research community, has 
been sufficiently enthusiastic that it seems entirely 
proper to look ahead at some of the key issues that 
need urgent resolution, in the reasonable confidence 
that the framework—at least for discussion—has now 
been set. I cannot cover all the issues but hope to 
address at least some of those that are likely to lie close 
to your hearts. 
Let me begin by taking you back to our terms of 
reference. While taking into account the NHS reforms 
and the functions and manpower review; and building 
on existing work, the Task Force is asked to: 
• take stock of the current situation with regard to 
the conduct and support of R&D in the NHS, to 
establish the nature and extent of any problems, 
and in that light to consider whether it is appropri-
ate to make recommendations; and, if it is: 
• to review the ways in which the NHS currently 
funds its own R&D and supports that funded by 
others; 
• to review the ways in which the NHS mechanisms 
for funding and supporting R&D promote and/or 
hinder the aims of the NHS R&D strategy and 
other Government policies relating to R&D in the 
NHS; 
• to advise on alternative funding and support mech- 
anisms for R&D, including any necessary transi- 
Forum 
In April 1994, a Taskforce under Professor Anthony 
Culyer's chairmanship reported its recommendations 
for funding research and development in the NHS. It 
was therefore appropriate for the 1942 Club [1] whose 
membership consists of academic clinicians and scien-
tists working on medical problems, to invite not only 
Professor Culyer to discuss the report, but also Profes-
sor Michael Peckham, director of research and develop-
ment at the Department of Health, who will be expect-
ed to implement the recommendations, and Mr John 
Cooper, chief executive of the Hammersmith Hospital 
NHS Trust representing NHS managers. Their 
presentations are published below. 
At an eariler meeting, the 1942 Club had heard from 
Mr John James [2], a member of the Taskforce and chief 
The recommendations 
The April 1994 Report of the Research and Develop-
ment Task Force Supporting research and development in 
the National Health Service [1] was quite deliberately 
long on principle and short on detail. This was not 
merely due to the pressure of time, though four and a 
bit working months was a desperately short time for us 
to tackle such a complex problem, but also because it 
was something for which we consciously strove, partly 
because we felt that there was a real need to set out the 
basics of a new framework for supporting research and 
development (R&D) in the National Health Service 
(NHS) (both the R&D of the NHS's own programme 
and the service support provided by the NHS for the 
R&D of others) and partly because we realised that the 
final details of the arrangements eventually to be 
adopted would depend upon a lot of specific work in 
the office of the director of R&D at the Department of 
Health (DoH), Professor Peckham, and upon much 
further consultation. After a hesitant start for a few 
months after the delivery of our Report on 30 April 
1994, the backing that it has received both from the 
A ) CULYER, BA, Deputy Vice-Chancellor, Department of 
Economics and Related Studies, The University of York 
donal measures, recognising that any new system 
will 
have to operate within available resources; and 
to report to Ministers by 30 April 1994. 
Our review and the conclusions from it are now well 
known and I 
do not propose to go through them in 
detail. It is important, however, to recognise that we 
ore 
 not charged with the task of considering the 
su
pport of medical and health services research in its 
entirety, let alone that of the fundamental sciences, 
Whether natural science or social science, on which all 
e lse  depends, whose interface between the more 
applied sciences of medicine and health services 
research is absolutely essential, and whose various 
sources of support are highly complementary. Some 
distinguished colleagues were disappointed that we 
had so little to say on this subject. My immediate 
response is to say that one needs to go one step at a 
time and there was always the risk that in attempting 
to tackle further complex and potentially controversial 
issues we might fail to satisfactorily address the 
important brief we were actually given. 
Basic with (not versus) applied science 
That the fruitful interplay between basic science and 
the more applied sciences is crucial can scarcely be 
emphasised enough. Few major innovations in health 
care do not have their roots in core disciplines such as 
physics, biochemistry or economics. Sir Colin Dollery 
summarised it concisely in the phrase 'science can 
change the rules of the game, development may 
improve the standard of play by existing rules'. I think 
by 'development' he means mission-oriented research 
and any that operates within a received scientific 
paradigm, which is not, of course, the concept of 
`service development' commonly understood in, 
say, trusts, which is characterised by the non-
generalisability of its conclusions. Basic science, 
whether it be in physics or economics, is rarely 
targeted at any specific use. It is speculative and inven-
tive, addressing questions generated by the imagina-
tion of the scientist in the search for greater generality, 
consistency and the solution of puzzles that may be 
absolutely fundamental. That kind of work is less com-
mon among clinical academics, who are more con-
cerned with solving clinical problems using the 
paradigms, theories and experimental methods devel-
oped within the parent disciplines and adapting them 
appropriately to the problems in hand. They are 
trained in both the clinical investigative skills and the 
laboratory methods required to address such prob-
lems, and they usually need access to patients though 
they often begin experimentation with animals or iso-
lated tissues. Mutatis mutandis, similar patterns can be 
observed in some at least of the social sciences which 
provide much of the core of health services research, 
With, for example, axiomatic structures of both 
behavioural theory and normative methods being 
developed by basic scientists, then applied and devel- 
Supporting R&D in the NHS 
oped over many years in empirical work (mainly statis-
tical, such as econometric), and then developed for 
specific purposes in health services research. Health 
services research sometimes involves the application of 
only medical science (as in clinical trials) , sometimes 
the application of only social science (as in estimating 
demand for health care) and sometimes it involves 
both types of science (as in many cost-effectiveness 
studies of medical procedures). I am not implying any 
meritocratic ranking to the activities of colleagues 
working in these various fields; the fruits of science, 
beyond the sheer intellectual delight of puzzle solving 
and the invention of explanations for phenomena 
(which is reward only to those engaged in it) inevitably 
depend upon a quite extended team of people having 
different skills and motivating passions. Moreover, that 
team is international, particularly, though not exclu-
sively, at the more general levels at which science may 
be conducted. 
However, the fruitful interaction between the con-
stantly developing 'science base' and its application 
along a continuum at the other end of which lies the 
practical implementation and use of procedures, is not 
linear. It is much better seen as a loop, and I conjec-
ture the more of a loop it is made to be, the greater 
and more valuable the eventual fruits. While the ideas, 
concepts, theories and so on that are 'applied' clearly 
in some sense have to precede the application, it does 
not follow that the organisation and support of 
research should follow in a compartmentalised or 
linear fashion. Applied science must apply, test, or 
develop the ideas and theories of basic science. The 
invention of valid ways of doing this testing and appli-
cation, whether laboratory-based in environmentally 
controlled experiments, or statistically-based and using 
the variation observed in nature and society, is a part 
of the imaginative excitement that draws many fine 
scientists into points along the continuum that are not 
`basic'. It therefore follows that applied scientists have 
much to learn from basic scientists and that, given the 
dynamic nature of scientific development, means must 
be found for frequent briefings and intellectual inter-
action, lest the more applied run down their intellec-
tual capital which they learned as graduate students 
and become incompetent in comprehending, inter-
preting and applying the work of researchers in more 
basic science. 
Applied with (not versus) basic science 
But a flow goes the other way too. While serendipity 
and curiosity have driven much research that has revo-
lutionised medicine and health care, the needs of 
health policy, which are, of course, broader than those 
of NHS policy, ought also to inform the research 
agenda in the basic sciences, or at least that science 
which is one step nearer the applied end of the spec-
trum than the most abstract. At one level, that means 
that we need better ways of identifying the needs of 
Supporting research and development in the 
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Forum 
	  
relates to funding. Before elaborating, 
i
let me digre, 
with some comments on the special ncrem ent 
 training and research (SIFTR). 
Conferring and funding 
Two issues arise. One is largely for institutions, espe-
cially universities, which must find ways of ensuring 
that the dialogue in the scientific loop is developed 
and nurtured. The ways in which we organise research, 
the geography of our universities, and the managerial 
leads given by deans, pro-vice-chancellors and the like 
are all crucial here. I do not think that, in general, our 
various quality control systems, or external scrutiny 
methods, or internal forward planning mechanisms 
typically pay much attention to these issues. They tend 
to be left to serendipity. 
The second is the question of who should pay for 
what. In the Task Force we were concerned only with 
the NHS's own R&D and its support for particular 
forms of applied research by others. This must include 
the hospital infrastructure that underpins the whole 
research endeavour, or at least part of it, partly 
because some of it depends on satisfactory patient 
flows of the right kind and partly because research 
activity is not easily, or sensibly, unpicked into parcels 
each with its own separate support structure. Much of 
the structure is shared. Moreover, there is also a shar-
ing with the teaching function, especially postgraduate 
teaching. Most researchers see the training of the next 
generation of researchers as one of their principal 
tasks. Moreover, they find that teaching, even at quite 
elementary levels, is one of the sources of inspiration 
for good research ideas. 
This has important implications. One is the undesir-
ability of creating walls between researchers within 
institutions. Another is the undesirability of creating 
walls between teachers and researchers (quite apart 
from the personal tensions and jealousies that such 
policies, pressed too far, would generate). Another 
SIFTR 
Although there was a common view that the R 
of SIFTR might have amounted to about 25% of the 
total, other voices could be heard suggesting that th
e T was 25% (this might have been the angle of o
ne 
seeking to maximise the amount of ring-fenced 
research money). It also seems to have been impli ed 
by some that, because the real rise in SIFT was onl y 
about 2%, at the time R was added to it 2% was the 
appropriate share of R (such might be the angle of 
one seeking to retain as much as possible within his or 
her institution). Not surprisingly, the DoH, in seekinz 
to advise ministers on the appropriate division of 
SIFTR into its T and R components conducted some 
multivariate econometric analysis. Its results were not 
very helpful. In my view, exercises such as these are 
fundamentally misdirected, and a range of 'guess. 
timates' of R between 2% and 75% is only to be 
expected. Let us take an analogy. Consider a sheep 
farmer producing sheep meat and wool. Some varia- 
tion in the quality and quantity of meat and wool 
might be possible in the short term by, say, varying the 
diet of the animals but, short of selective breeding, or 
mixing breeds in one's stock, meat and wool are pro-
duced in pretty fixed proportions and, to all intents 
and purposes, jointly. It makes no sense to ask 'is the 
fodder the cost of the wool or the cost of the meat?' By 
variation in feeding one might be able to estimate the 
marginal cost (in fodder) of more or better meat, or 
more or better wool. But that is marginal cost and not 
the same as apportioning the total cost between the 
meat and the wool. Much the same is true of teaching 
and research, and also of the different types of 
research alluded to before. The proportions may not 
be strictly fixed, but in centres of research excellence 
and postgraduate education they are variable only 
within fairly strict limits. Hence, it is not sensible to 
seek to separate the total costs of teaching and 
research, nor of types of research, where so much is 
complementary and mutually reinforcing. So what 
should one do? The sheep market can give us some 
clues. The approximate fixity of the proportions  of 
meat and wool produced, and the impossibility of sep-
arating the total cost of rearing sheep into the costs of 
wool and the costs of meat, do not prevent each com-
manding its own price. The prices are determined by 
the interaction of the costs of rearing sheep and the 
demand for the various sheep products (plus, of 
course, much meddling in the form of the Common 
Agricultural Policy). In our case, what we have needed 
to resolve our puzzle is a revelation of the demand for 
teaching and research. This is not so much a matter 
for markets to determine as for the public sector 
finders, who are our principal demanders in the sense  
that they 
determine what R and what T shall be pur-
cha
sed (with various degrees of precision in the identi-
fication of the 'product' being purchased). And this, 
o
f course, is what happened in the case of SIFTR. In 
the end, a public judgment by the accountable minis-ter had to determine what the split between T and R 
should be. Under the new arrangement proposed by the Task 
Force, we need to develop this approach further. 
Policy towards our major centres of training and 
research needs to recognise both the mutual comple-
mentarity of the activity and that much of the infra-
structure supports both. Within the R&D field, the 
same applies a fortiori. 
The NHS's R&D strategy is chiefly focused on health 
services research. The new funding stream will add to 
this the R of SIFTR and the special research funding 
of the London postgraduate teaching hospitals. In the 
allocation of the latter, it will be essential to recognise 
the complementarity between T and R and the infra-
structure support of both. It will also be necessary to 
recognise that the research infrastructure also 
supports a wide variety of R&D activity, most of it in 
fact the NHS's own programme. 
In emphasising the different sorts of criteria that 
will need to be borne in mind in allocating infra-
structure support (what we called 'facilities support') 
and the NHS service costs of research on the one 
hand, and support for projects and programmes on 
the other, I am not suggesting that the NHS R&D 
strategy has been short-term, and narrowly utilitarian. 
The R&D strategy is far from exclusively short-term and 
immediately utilitarian: for example, it has long sup-
ported fundamental research in outcome assessment; 
it is funding a set of projects on methodological topics; 
it has recently set up the Manchester-based research 
centre in primary care with a long-term contract. The 
usual way in which R&D has been commissioned has 
been by inviting tenders for somewhat generally 
defined topic areas which afford researchers an oppor-
tunity for developing or piggy-backing their own 
research priorities on to those of the strategy. Regions 
have often supported the imaginative establishment of 
new research centres and specific academic posts 
with general briefs that satisfy the most jealous 
guardians of the principle of academic freedom. So let 
us not dismiss the R&D strategy of the NHS for what it 
is not. 
Special centres 
It is also clear that some scientific concentrations, 
combining aspects along the scientific spectrum from 
basic to applied, benefit from being very large indeed. 
They have usually been developed with the combined 
support of the Funding Council, the NHS, the MRC 
and one or more major charities such as the Well-
come, and in such cases this collaboration is essential 
and highly beneficial, provided the internal manage- 
ment plays its role appropriately. Obvious examples of 
such centres are the John Radcliffe at Oxford, the 
Hammersmith and University College London, in 
London, Addenbrooke's in Cambridge, and in Edin-
burgh the Royal Infirmary and Western General. They 
should not, of course, be supported simply because 
they are there, regardless of the outcome of on-going 
scrutiny; nor should the emergence of other centres 
be prevented simply to protect those that are estab-
lished but unable to compete in open competition. 
Moreover, a very large scale is not always either neces-
sary or desirable. One of the emphases of the Task 
Force's report was that in the future support should 
focus more on individuals and teams and not be solely 
institutional, the latter being justified only when many 
individuals and teams worth supporting were all mem-
bers of the same institution or a set of collaborating 
institutions. But some of these centres, including those 
mentioned, have been less successful at developing the 
multidisciplinary health services research arm that 
would fully complement their clinical and basic natu-
ral science strength. Indeed, I doubt whether some 
have tried very hard. Further, some of these institu-
tions have made no serious attempts to extend their 
research significantly into the community or train 
cadres of researchers of the first rank capable of doing 
it. (I am not suggesting that every institution, or 
indeed any single one, ought to invest across the whole 
spectrum; I am merely observing how few in London 
have invested in non-clinical health services research). 
The R&D forum 
I conclude that partnership in supporting research (and 
teaching) is essential and should be furthered for 
major centres with many specialist disciplines, operat-
ing along substantial lengths of the spectrum from 
basic to applied. This is not to say that the separation 
of the R from SIFTR was ill-advised. On the contrary, 
the need for greater clarity and more careful targeting 
was a recurring theme in the evidence the Task Force 
received. There are four major interested parties with 
stakes in this matter. On the research sponsoring side 
they are the NHS R&D directorate (DRD), the Higher 
Education Funding Council for England (HEFCE), 
the research councils, especially the MRC, and the 
major charities. On the other side is the research and 
training community, especially the universities. What 
we seem to have lacked in the past is a formal mecha-
nism for debating these various issues (who should be 
supporting what, on what scale, by what criteria and in 
what kind of partnership?) and agreeing on a broad 
policy between them. The Forum, which was the first 
recommendation of the Task Force, would be just such 
a body (a kind of comprehensive research liaison 
group), perhaps with a working party supplemented 
where necessary with members representing other 
interests, to consider the matter. I hope Professor 
Peckham will make this an early item for the Forum, 
health policy and of the NHS for R&D. Professor Peck-
ham has made revolutionary strides here in the past 
few years but much work still remains to be done, 
especially in enlisting purchasers' commitment to 
these processes. At another, it means that basic scien-
tists must listen to the applied researchers to find out 
what holds them back from making even more effec-
tive contributions. In my own field, a good example of 
this sort of interaction has been the development of 
outcome measures, which is now quite a thriving 
industry involving applied researchers as well as engag-
ing the interest of theorists in various social sciences. 
An area where we urgently need work if the fruits of 
science are more effectively to be brought to the 
advantage of ordinary people, concerns the question 
of how to change the behaviour of practising doctors 
and other medical professionals in ways that are con-
sistent with what good theory and good empirical 
research have shown to be effective. (My examples 
from sciences that are neither natural nor medical are 
deliberately chosen to illustrate the generality of what 
I am claiming.) 
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whose terms of reference were announced just before 
Christmas 1994 and whose members are in the process 
of being selected: 
• To advise the Director of R&D, and through the 
DRD the Secretary of State for Health, on: 
a current national and international strategic 
issues relating to R&D of importance to the NHS 
b advances in science and technology which may 
have an impact on health 
c technology transfer, covering links between basic 
science, applied research and health services 
d the development of coordinated systems for 
information derived from and about research 
e the capacity, and ways to increase the capacity, 
for undertaking R&D, including health services 
research, needed by the NHS 
f any other matter relating to R&D remitted to the 
Forum by the DRD. 
• With a view to setting a strategic framework for the 
Central Research and Development Committee 
(CRDC), to advise the DRD, and through the DRD 
the NHS Executive Board, on: 
a the overall pattern of funding for R&D, and the 
plans and priorities of individual research 
funding agencies 
b the need for NHS support for externally 
sponsored R&D within the NHS 
c progress on the establishment and operation of 
new systems for funding and supporting R&D in 
the NHS. 
Facilities support 
The Task Force recommended that future financial 
support from the 'single funding stream' should take 
three forms and, in addition, that the R&D Informa-
tion Strategy, with its emphasis on dissemination of 
research results and the promotion of their uptake, be 
supported and that research capacity be further inves-
tigated and supported. The three forms of financial 
support were the direct and indirect costs of research 
projects and programmes, the 'excess' service costs of 
approved peer-reviewed non-commercial research, and 
support for research facilities in trusts and other NHS 
research providers. 
Facilities support is intended to cover the costs of 
maintaining or creating particular research facilities 
and staff to enable R&D projects to take place which 
cannot reasonably be attributed to a specific project or 
programme. We envisaged that some programmes 
would themselves entail facilities support which would 
be embodied in the contract for such programmes, 
and this meant that the future system had to guard 
against the possibility of double counting in the form 
of supporting any particular activity twice over. I have 
already emphasised that facilities funding for NHS 
R&D needs to be considered alongside the other R&D 
and teaching activity of major centres. 
One of the issues that has cropped up in subsequ ent 
 discussions, and about which the Task Force itse l f 
 made no recommendations, is the issue of facilities in 
 the form of capital, especially funding for buildings. (I 
am not here referring to the specific needs for capit al 
that result from the major restructuring of London 
institutions.) Some, if not all, of the major centres f or 
 excellence (which need not be large) face severe con-
straints in their capacity to take on additional research 
activity, particularly through a lack of suitable space to 
accommodate the researchers and their associated 
other space needs. Several important issues need to be 
resolved in this connection. One is whether Treasury 
rules would permit the use of what I understand to be 
recurrent money for capital purposes; another is the 
question of the ownership of any such estate created in 
this way (especially when it is not a part of trust 
property), and another is the question of whether the 
conventions about investment appraisal procedures 
ought to be (or, indeed, could be) followed in the 
same way in such cases, supposing that the other two 
problems were resolved. It is also unlikely that satisfac-
tory answers to these issues are to be found simply by 
relying on the market: for example, by channelling 
recurrent support only to institutions that have spare 
capacity and therefore lower marginal costs of supply-
ing research, because these institutions may not be the 
best places for that research to take place. Good 
research, and good cost-effective research, is not nec-
essarily the cheapest research. This problem may 
become acute for health services research that does 
not depend upon a specifically NHS base and which 
would be unsuitably located on trust property. This 
may particularly apply to research based in universities 
or in fundholding general practices. It is not clear 
whether the answer lies in developing some supple-
mentary capital funding sources within the NHS for 
such support, or for extending loan arrangements or 
rental agreements. Again, this seems an issue pre-emi-
nently suited to a preliminary discussion at the new 
Forum. The issue of marginal capital costs of research 
is not solely one that concerns the NHS's own R&D 
programme but also the programmes of the medical 
charities and the research councils. 
Service costs 
One of the issues that led to the establishment of the 
Task Force was a perceived threat to clinical trials, 
especially multicentre trials and trials in highly spe
-
cialised units with difficulties in recruiting patients in 
sufficient numbers, and to major centres dependent 
on tertiary referrals, in the form of a reluctance in the 
new NHS among purchasers to buy services inflated by 
research costs and by trusts to accept service contracts 
that make-no allowance for research costs. A necessary 
if not sufficient condition for resolving this issue is to 
identify both the research and the service costs and to 
ensure that these are built into service and research 
contracts in ways acceptable to the institutions on 
w
hom the costs would fall, and which are seen as fair 
and acceptable to service purchasers and research 
sponsors. Until appropriate conventions for the cost-
ings have been developed, regional directors are being 
urged to smooth the passage of such research by 
reminding institutions that the R of SIFTR is intended 
partly for this purpose and, where necessary, by using 
regional funding to support, for example, service costs 
in research into general practice. A set of conventions 
will need to be developed to cover the various ways of 
sharing the patient costs between service purchasers 
and research sponsors. It is unlikely that a simple and 
standard formula will do the job. There is, after all, a 
major difference between a research project in which 
an entirely new procedure is being investigated, where 
the entire exercise might be considered to be 
`research', and one where there is a relatively minor 
additional cost in the form of extra patient investiga-
tions and only marginally longer spells of hospital 
inpatient stay. Any such future conventions are likely 
to be highly dependent on the brokering role of 
regional directors of R&D (RDRDs) and the depth of 
their relationships and the mutual trust they have 
established with their local research communities and 
health care commissioners. This is an area where the 
subtle managerial skills of RDRDs will most be needed. 
Moreover, in some areas it will not be enough for R&D 
merely to respond to the patterns of referrals that 
might emerge in the market for medical care: for 
some groups the research needs for patients may 
require a planned concentration of such referrals and 
active intervention to secure it. 
Quality assessment and assurance 
We regard peer review as the main plank of quality 
assessment and assurance. However, we recognise that 
this is not only a costly exercise, especially of the time 
of researchers themselves, but also that some of the 
`Cinderella' areas of research in community care 
might be vulnerable to the early application of a fully 
rigorous system of peer review. In time, however, we 
expect that this field would be treated no differently 
from any other. 
There are notable lacunae in the present scope of 
peer review which are less defensible. In our view all 
R&D which uses NHS resources (including patients) 
should be subject to peer review, including 'implicit' 
research funded out of trust funds, or the smaller 
charities, or industry. Moreover, we do not necessarily 
see peer review as having to be focused solely on 
projects; there is much to be said (though we did not 
say it!) for concentrating, where appropriate, on indi-
viduals, whose track record or promise suggests that 
giving them a relatively free hand would be a produc-
tive way of spending some of the NHS's R&D funds y  
(not to mention the research councils'). 
Some alarm has been expressed at our proposals for  
an HEFCE or Thompson Review type of quality assess-
ment that included researchers not currently eligible 
for inclusion in the research assessment exercise 
(RAE), to back up the facilities support element of our 
proposed financial package. My own view is that, with-
out the cooperation of the HEFCE, any such indepen-
dent exercise would be far too costly. However, prelim-
inary discussions between the NHS Executive and the 
Funding Council give cause for hope. The simplest 
and least bureaucratically costly thing would certainly 
be for the HEFCE to agree to extend the range of its 
enquiry by creating appropriate new units of assess-
ment or extending existing ones, especially into 
applied topics, and to consult the R&D Directorate in 
the composition of the panels. It seems intolerable to 
subject universities to a research assessment exercise 
(RAE) in 1996, 1997 and 2000, so I do not expect any-
thing much to be possible before 2000. Until the out-
come of that exercise (assuming it to be extended as I 
have suggested) 'facilities' support will have to make 
do with such external quality judgments as are avail-
able, unless arrangements can be made for a minor 
exercise in 1997 that focuses only on those research 
active staff not included in the 1996 exercise. 
Cinderella subjects 
The Task Force drew attention to the importance of 
R&D in community settings for health care and in 
developing research strengths in the main disciplines 
likely to be involved. Some of our recommendations 
were directed to the opening up of the funding stream 
to make it more accessible for these purposes and to 
support service costs of such research. Without this, we 
can hope for little in the way of any transformation of 
the culture of the NHS towards awareness of relevant 
research outcomes and the implementation of prac-
tice informed by them, especially given the increasing 
role of general practitioners as purchasers. Culture 
change is needed not only for medical practitioners 
but also for the nursing profession and the other allied 
professions. The community is increasingly the setting 
for health care, and it is therefore a matter for con-
cern that of the 29 nursing units assessed in the last 
RAE, none scored 5 (the highest), only three scored 4 
and two 3; and that of the 34 units of assessment in 
other studies allied to medicine, there were only two 5, 
five 4 and one 3. My own feeling is that we shall have 
to target a few of the best existing centres in order to 
develop both the necessary training and the com-
munity research partnerships. This might well be an 
early matter for the newly constituted Central R&D 
Committee to consider. We were told that there are 
technico-legal difficulties in offering facilities support 
to fundholders. At the very least I would hope to see 
some major support of a programmatic sort for work 
in this field and a workable way of supporting any 
service costs of such research. 
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Contracts and bureaucracy 
Whatever arrangements are adopted in future, they 
should minimise the costs of bureaucracy and manage-
ment both for the NHS and the research community. 
While it seems inevitable that some of our proposals, 
such as the new costing arrangements for R&D with 
service cost implications, will create further expenses 
on both sides, it was our judgment that they would be 
worth it provided that they are kept at the minimum 
necessary, especially if the alternative were for good 
research never to get off the ground or to wither once 
it had. One must not allow the perfect to become the 
enemy of the merely good—especially if the 'perfect' 
is ultimately self-destructive. 
It is important not to infer that the increased use of 
`contracts' for R&D necessarily implies rigidity or 
short-termism. The Task Force saw no reason why con-
tracts should not be as flexible and embody as much 
individual discretion for researchers, as the circum-
stances and common sense demand. Moreover, we saw 
no reason why 'contracts' should be perceived as 
inherently short term. They could be (as indeed some 
have) awarded for long periods, ten years or more 
(the latter, for example, in cases where senior posts are 
being supported). Nor does a contract have to be 
made artificially specific. The advantage we saw in an 
intelligently interpreted system of contracting was its 
explicitness about what was going to be done (even 
making a research 'fishing expedition' explicitly just 
that), how success or failure would be judged, and 
what the work ought to cost. None of us in the 
research community ought to have the right to use 
public money in a casual manner and for implicit pur-
poses with no attempt to assess the value of that 
activity. 
Declaring implicit research in trusts 
One of the quantitatively most difficult issues, which 
the Task Force did not attempt to resolve, was the size 
of support for research that service providers fund on 
their own account, partly out of special trustee 
accounts, or out of patient care contracts partly with 
the agreement of purchasers, and partly only implicitly 
so. We had no hard evidence on the size of this last 
component, which we called 'implicit' research, but 
were advised that it was a very large sum. It includes 
R&D sessions in consultants' and other staff contracts. 
It also includes much work by clinical scientists in 
trusts. In the internal market for patient care, this 
funding is plainly at risk, for it seems extremely un-
likely that it could all become embodied in explicit 
contracts for R&D made with any trust's purchasers, 
even if more did. We were told that such research is 
often an important preliminary to more substantive 
and explicit research, but much of it may also be sub-
stantive (though it must be said that a lot of it is not 
peer-reviewed, even when it entails higher patient care 
costs—in which case we argued that it should be su bpj  
ject to peer-review). It seemed to us important that 
these funds be protected for R&D and we proposed 
that they be progressively declared by trusts and added 
to the single funding stream. The word 'progressive 
needs underlining and made more clear than w e 
 made it in the Report. 
In one sense, 'progressive' means that we did not 
expect trusts to be able to identify and therefore 
declare all such implicit research with great accuracy 
and at a moment's notice. One approach would phase 
declaration over time, so the recurrent stream from 
this source would build up in a cumulative fashion. 
But, if trusts are to have any incentive at all to declare 
all the costs of implicit research, they must clearly be 
reassured that declaration will not be immediately to 
lowed by `confiscation'—which is how it might appe 
in a system that removed a sure current resource an 
substituted in its place the uncertain prospect of get-
ting it (or more, or less) back by competition for a 
share of the consolidated stream of funds. Such funds 
as are declared by trusts should therefore be regarded 
as at their disposal long enough to make it worth their 
while declaring them. There is the risk of creating a 
classic prisoner's dilemma, in which trusts collectively 
might concede the long-term benefit of identifying 
and protecting this money, and acknowledge the Task 
Force's arguments in favour of allocating it more effec-
tively, yet individually see such a disadvantage to doing 
so that they all end up in the worst of all possible 
worlds, in which increasing competition in the patien 
care market causes this element of R&D funding t 
shrivel up altogether. The risk with this gradualist pr 
gression is that, despite incentives, many may still not 
declare, or not declare much, so the yield would be 
small and the overall resource eventually be seen to be 
too small. 
An alternative, to which I incline, is to prepare early 
guidance and ask trusts to make the best estimate they 
can of their current annual spend on implicit 
research, allocating it as 13st they can to our three 
categories: project and programme direct and indirect 
costs, service support costs, and facilities or infra-
structure. Such declared funding would still need to 
be protected for a reasonable period for those declar-
ing it, but this approach would have the advantage of 
getting this element immediately and roughly compre -
hensively into the new single funding system. Subse-
quent periods would then be opportunities for further 
refinements and more accurate allocation across the 
three types of support, rather than a progressive build-
up of the total contribution of this element to the total 
funding stream. 
Special treatment for London? 
London undoubtedly contains some of our finest 
research institutions and largest concentrations of 
expertise across the spectrum and along many relevant 
branches of science, though it has by no means a 
monopoly on excellence. Nevertheless, the greatest 
concentration of excellence is in London: it has taken 
decades to build and could be destroyed in months. 
One can make criticisms and see weaknesses. Most of 
the best health services research is not done in Lon-
don at all: there are many 4 and 5 rated clinical units 
of assessment outside London. Moreover, London is 
costly. That is true not only for service provision but 
also for teaching and research. Nonetheless, such 
excellence is worth preserving and it is my belief that 
the various forms of support for R&D which the Task 
Force proposed should be sufficient to ensure the 
future of the best institutions, departments and units 
that are there, as well as any that might develop, pro-
vided that R&D costs and expected outcomes can be 
explicitly evaluated, and provided that the allocation 
of facilities support gives due recognition to the 
demonstrable and demonstrated needs of nationally 
important centres. However, neither the market for 
patient care nor the evolving market for R&D will be 
sufficient to produce sensible results if left to operate 
without some further controls and central direction. 
These issues arise particularly for those groups which 
depend on tertiary referrals, and for other centres of 
specialist excellence. Arguments can be made on both 
sides for keeping some centres of expertise in the 
capital or for developing them further in major 
research concentrations in other parts of the country. 
But what would be intolerable and have disastrous 
effects on morale would be for such responses to 
market pressures and individual initiatives to take 
place in dribs and drabs which debilitate extant teams 
of researchers and slow down the ability of others to 
develop the necessary critical masses. That way lies 
mediocrity and second-rateness and the destruction of 
some of our best institutional reputations. 
If anyone really believes that major concentrations of 
excellence of the sort found, for example, in the Ham-
mersmith and University College London, are at pre-
sent on sites that are too costly, then the implied need 
for change will have to be discrete rather than 
marginal, and will need to be planned with great care 
to preserve teams, networks, extant programmes, and 
individuals' careers, and be supported with appropri-
ate capital funding. Any such change would, of course, 
be hugely costly and disruptive. On the other hand, if 
one does not believe this to be the case, then it may be 
necessary to devise a quasi-permanent system of sup-
plementary support from the collaborating partners 
which enables the research activity to continue where 
it is so long as the quality assessments warrant it. There 
is no case for general institutional subsidies whose ulti-
mate destination and effects are untraceable and can-
not be accounted for. Properly handled, facilities 
support is there to meet this need, and could do so in 
a more sensitive and carefully targeted fashion than 
the R of SIFTR or the current temporary arrange-
ments for the London postgraduate teaching institu- 
tions. After all, cost-effectiveness in R&D is justified by 
the same ends as cost-effectiveness in inpatient 
care—the more efficiently R&D resources are hus-
banded, the more R&D work they can do—the more 
the outcome from our limited R&D resources. And, as 
mentioned earlier, research that is merely cheap is not 
necessarily good nor cost-effective. There is no reason 
why facilities support, or indeed either of the other 
two forms of support, should not recognise that some 
centres are inherently costlier than others. 
The best groups have nothing to fear from a pur-
poseful attempt to address these issues. They need to 
be considered against a background of policy towards 
concentration of specialist centres, their needs for par-
ticular sizes of flows of patients, the academic quality 
of the institutions (and its within-institution variance), 
and the relative costs and quality claims that can be 
mounted by competitors. This is not something for the 
R&D programme of the NHS to solve on its own: it 
also particularly involves the Funding Council, the 
research councils, and the large research charities. It 
also involves health service purchasers whose willing-
ness to pay their share needs to be assured. 
Can purchasers be persuaded? 
It has been said that the Task Force's strategy of devel-
oping the single funding stream as a levy on pur-
chasers (including fundholding general practitioners) 
is highly risky, given their extremely uneven commit-
ments to (and experience of) R&D, for which there 
was much evidence from our consultation. I have to 
agree with the riskiness of it, but take the view that the 
risk is there anyway. It would only be window-dressing 
to fund R&D support by, say, top-slicing the budget 
centrally. Purchasers, collectively and individually, will 
be perfectly well aware that R&D funding comes at the 
opportunity cost of current health care purchases, 
whatever the mechanisms (as, indeed, current health 
care is purchased at the opportunity cost of R&D). We 
were anxious to strengthen the voice of purchasers in 
the priority setting process, both centrally and at 
regional levels, so as to ensure that the priorities of the 
NHS R&D programme reflect the needs of the NHS, 
partly because their collaboration is essential (for 
example in ensuring that adequate numbers of suit-
able patients are available for research of various kinds 
and with the funding support of many different 
funders) and partly because they must be involved in 
the strategy for promoting evidence-based health care 
(which should be more than just an information 
strategy). The levy symbolises the seriousness with 
which the voice of purchasers is to be taken and is also 
a signal to central R&D managers and to the research 
community in general that the task of creating a 
widespread research-oriented culture in the NHS has 
to command a high priority. If we fail in this task over 
the next few years, the consequences could be very 
grave for the future of R&D in the NHS and would 
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have been so whatever the precise form in which the 
funding stream was presented. We hope to have given 
it a sharp focus and to have concentrated minds. This 
endeavour will probably need systematic orchestration 
by the new Central RDC and Professor Peckham's 
R&D directorate. 
Envoi 
It has been extremely gratifying that the work of the 
Task Force seems in general to have received so 
uncompromising a welcome and that it should com-
mand the interest and commitment of the Secretary of 
State herself. We are plainly into serious business. The 
stakes are high but the future augurs well. I am much 
impressed with the strong support for the research 
community that emanates from Professor Peckham's 
division and with its strong commitment to networking 
and consultation. The Task Force was concerned to 
ensure that the transition be as smooth as possible and 
I detect a commitment to this too. However, its suc-
cessful implementation will also require the support 
and collaboration of the research community. 
Much of the environment in which we operate today 
is not particularly friendly to the research community. 
Decision makers need to be convinced that there is a 
pay-off to R&D and that we have our research houses 
in good order. The Task Force's framework should 
enable us to offer these assurances but, in the end, it is 
the research community which has to provide the 
proof of the pudding and to supply Professor Peckham 
with plausible—and empirical—arguments. Mere 
assertion will not do. It will be especially important for 
us to convince purchasers too, and to enlist their sup-
port and commitment in a world where the levy will be 
seen to be in direct competition with current health 
care funding. 
I hope you will not bring to this a frame of mind 
that hearkens back to some past, and probably mythi-
cal, halcyon era. There is no point in wishing the prob-
lems away or regretting the history that makes the 
proposed changes necessary. There is no point in com-
paring today with things a decade or two ago. But 
there is every point in comparing what you imagine 
the research world would have been like in five years' 
time, had we merely gone on as we are, with what it 
can be like post-Task Force. My own opinion is that 
disaster lay ahead, not only because of the effects of 
the internal market for patient care on research but 
also because there was so much that was opaque, 
creaking, unfair and inappropriate in the accretion of 
history. I am by nature an optimist who tries to ensure 
that his own institution sees every potential threat as a 
real opportunity. But for us all to realise these oppor-
tunities in the sort of world envisaged by my Task 
Force colleagues and myself requires us all to promote 
a dramatic culture change, to get the national frame-
work right, and to ensure that our own institutions are 
poised to take full advantage of it. 
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The implementation 
Three years ago at a meeting of the 1942 Club 1 out-
lined proposals for a research and development strate-
gy and programme for the National Health Service 
(NHS): The development of this initiative since 1991, 
together with the new arrangements for supporting 
research and development (R&D) in the health ser-
vice, presents a unique chance to create a strong base 
for research and an effective interface between the 
NHS and science. It is important now to take full 
advantage of these opportunities. 
Since 1992 a regional and central infrastructure for 
NHS research and development has been established 
with a growing portfolio of research. Its emphasis lies 
in the systematic analysis of practical problems facing 
the health service and the mobilisation of existing 
research information through the Cochrane Centre 
and the Centre for Reviews and Dissemination in York. 
Through the Standing Group on Health Technology 
attention has been focused on the evaluation of new 
and existing methods of health care. A stronger rela-
tionship between the NHS and the science base has 
been sought through the concordat with the Medical 
Research Council, agreements with the new research 
councils (Biotechnology and Biological Sciences 
Research Council, Engineering and Physical Sciences 
Research Council, Economic and Social Research 
Council), interaction with the charities and through a 
number of initiatives with industry. 
The NHS is making substantial investments across a 
wide range of R&D functions. They include the sup-
port of the Medical Research Council (MRC) and 
other clinical research within the NHS, research 
focused on NHS problems, the NHS interface with sci-
ence and technology, the synthesis and analysis of 
existing research knowledge, the practical application 
of research outputs and the support of an NHS tech-
nology scanning function. The purpose is to create a 
continuously updated knowledge base for strategic 
and clinical decisions. 
As this programme evolves it is essential not to lose 
sight of the unifying purpose which is to use R&D to 
MICHAEL PECKHAM, MD, FRCP, Director of Research and 
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obtain the best quality of care achievable with available 
resources. The desired outcome will find expression in 
the improved health of the population, as well as in 
Wealth creation and other economic benefits to the UK. 
The scope of NHS R&D 
The commitments and scope of NHS R&D are 
summarised in Table 1. Details of the various initiatives 
associated with each of the components of the pro-
gramme are given elsewhere [1-9]. 
Background to the NHS Research Taskforce (Culyer) 
rehpeo r 
first O towards new arrangements for support- 
ing 	
s] T 	 tep 
research in the NHS was taken at a meeting 
between the NHS Management Executive, the region-
al general managers and the regional directors of 
Research and Development on 8 October 1993. The 
agenda was devoted to one topic, 'the service market 
and research and development: achieving synergy'. 
The purpose of the meeting was to devise a way to sup-
port R&D in the reorganised NHS to assist the health 
service to fulfil its purpose. To be effective, purchaser-
provider contracts depend upon research information 
as obtained for example, from the Concorde trial of 
AZT in asymptomatic HIV positive people, which had 
recently shown the potentially important impact of 
research on clinical practice [11]. At the same time, 
because clinical trials may incur increased service 
costs, purchasers and providers may be discouraged 
from adding their support. Consequently, unless new 
arrangements could be devised, the assessment of 
health care interventions and other research could 
experience difficulties. Following discussion of the 
issues involved, it was proposed that a system should 
be devised for separating research funding from the 
costs of patient care. A paper entitled 'Achieving 
synergy between the NHS patient care market and 
R&D' proposed the formation of an NHS Research 
Taskforce; this was announced by the Minister of 
Health in November 1993. 
The status quo was not an option since the arrange-
ments for supporting clinical research were not 
functioning satisfactorily. As a comment in The Lancet 
put it, 'The fragmentation of research funds was not 
created by the market nor was the duplication that this 
Catilead to. Long before the market the support that 
hospitals received for the increased service costs 
arising from research was unpredictable and hap-
hazard and meant that some high quality projects 
failed whereas some poor quality programmes were 
supported' [12]. Over the past two years, through the 
efforts of the regional directors of R&D, funds have 
been made available to support MRC clinical trials 
Within the NHS on a one by one basis. But such 
arrangements  were clearly not sustainable in the 
long 
 
Table 1. Research and development in the National 
Health Service: commitments and scope 
• Funding applied health research directed at NHS prob-
lems 
• Analysis and synthesis of research findings 
• Transmission of research information to clinicians and 
other users 
• Measures designed to promote the uptake and practical 
application of research findings 
• Provision of support within the NHS for research funded 
by the MRC and charities 
• Provision of appropriate training in applied health 
research and the support of trained personnel 
• Provision of an efficient NHS testbed for research funded 
by industry 
• Mechanisms for relating the NHS to science and technol-
ogy including a scanning function to provide awareness 
of imminent and likely future developments 
• Assisting new developments arising from science and 
technology 
• Systematically evaluating the costs and benefits of health 
care interventions 
• Mechanisms for intellectual property 
• Mechanisms for supporting NHS R&D 
• Assessing returns on investments in R&D 
The environment for research is changing and these 
changes are not confined to the UK. The new environ-
ment is being shaped by several factors. Prominent 
among them are changes in health services and the 
spectacular advances in science and technology. In the 
UK, as in other countries, there is increasing emphasis 
on the non-healthcare determinants of health includ-
ing socio-economic factors, transport, environment 
and lifestyle; there are perceptible changes in public 
interest and understanding of health issues; there are 
also new ethical and medico-legal considerations and 
new challenges for education and training. To these 
factors should be added a general emphasis on selec-
tivity in the use of funds and on the returns on invest-
ments in research. 
Recently, there have been indications of a degree of 
malaise in the performance of UK clinical research. 
The Science watch report of March 1991 [13], for 
example, documented UK clinical research publica-
tions between 1981 and 1990 and noted that the 
citation impact had fallen by almost 9%. This decline 
has been in evidence since the beginning of the 1980s 
and there has been a concomitant increase in uncited 
articles. 
Implementation of the taskforce recommendations 
R&D budgets are, at present, allocated through differ- 
ent mechanisms and with varying criteria (Table 2). In 
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